Alcon and Aerie Pharmaceuticals Inc. have entered into a definitive merger agreement through which Alcon will acquire Aerie in a transaction valued at approximately $753 million.   The acquisition expands Alcon’s footprint in the ophthalmic pharmaceutical space and is expected to add broader R&D capabilities to its existing commercial efforts.   Alcon will add the commercial products netarsudil and latanoprost ophthalmic solution (Rocklatan) 0.02%/0.005% and netarsudil ophthalmic solutio...